Reactions 1704, p221 - 2 Jun 2018 Hypertension: case report A woman in her 50s [exact age not stated] developed hypertension during treatment with lenalidomide and rituximab [routes not stated; not all dosages stated] for recurrent marginal zone lymphoma (MZL). The woman, who had MZL, started receiving standard R- EPOCH chemotherapy, which included rituximab, etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin [hydroxydaunorubicin]. After receiving six cycles, she achieved a complete remission status. She remained in remission for eight months, after which she presented with a symptomatic relapse. Thereafter, she was enrolled in a clinical trial and started receiving treatment with lenalidomide 20mg and rituximab. She tolerated the first two cycles and all the disease related symptoms resolved. However, she experienced worsening hypertension. The woman’s lenalidomide therapy dose was reduced to 15mg starting from the third cycle. Five months after the enrolment, she was pulled out from the study following a hypertensive emergency episode [outcome not stated]. At that time she was in complete remission, which continued for the following two years despite not receiving any additional therapy. Author comment: "She was enrolled in a clinical trial assessing the role of different maintenance regimens after induction with lenalidomide and rituximab. The patient tolerated the first two cycles well with resolution of all disease related symptoms, however she developed worsening hypertension". Ibrahimi S, et al. Sustained response to lenalidomide for early relapsed marginal zone lymphoma. Blood Cells, Molecules and Diseases 71: 53-54, Jul 2018. Available from: URL: http://doi.org/10.1016/j.bcmd.2018.02.004 - USA 803324050 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704
Reactions Weekly – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera